Insider Selling: Bolt Biotherapeutics (NASDAQ:BOLT) VP Sells 4,077 Shares of Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) VP Sarah Nemec sold 4,077 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $13,209.48. Following the transaction, the vice president owned 17,082 shares in the company, valued at approximately $55,345.68. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sarah Nemec also recently made the following trade(s):

• On Thursday, September 17th, Sarah Nemec sold 2,922 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.32, for a total transaction of $9,701.04.
• On Wednesday, September 16th, Sarah Nemec sold 843 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.77, for a total transaction of $3,178.11.

Bolt Biotherapeutics Trading Up 0.8%

BOLT stock traded up $0.03 on Monday, hitting $3.59. 22,454 shares of the company were exchanged, compared to its average volume of 27,365. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61. The stock has a market capitalization of $6.93 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. Bolt Biotherapeutics, Inc. has a twelve month low of $3.10 and a twelve month high of $7.20. The business’s fifty day moving average is $3.84 and its two-hundred day moving average is $4.29.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. As a group, research analysts forecast that Bolt Biotherapeutics, Inc. will post -11.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

BOLT has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $14.50.

Hedge Funds Weigh In On Bolt Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nan Fung Group Holdings Ltd purchased a new stake in Bolt Biotherapeutics during the 2nd quarter worth $19,250. Renaissance Technologies LLC raised its position in Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares during the period. Finally, T3 Companies LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at about $208,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.